2026年安进历年年报/社会责任报告/ESG报告合集（共37套打包）

1、News ReleaseOne Amgen Center DriveThousand Oaks,CA 91320-1799Telephone 805-447-AMGEN REPORTS FOURTH QUARTER AND FULL YEAR 2025 FINANCIAL RESULTSTHOUSAND OAKS,Calif.(Feb.3,2026)-Amgen(NASDAQ:AMGN)toda。

2、February 3,2026Q4 25 Earnings Call2Provided February 3,2026,as part of an oral presentation and is qualified by such,contains forward-looking statements,actual results may vary materially;Amgen discl。

3、News ReleaseOne Amgen Center DriveThousand Oaks,CA 91320-1799Telephone 805-447-AMGEN REPORTS THIRD QUARTER 2025 FINANCIAL RESULTSTHOUSAND OAKS,Calif.(Nov.4,2025)-Amgen(NASDAQ:AMGN)today announced fin。

4、November 4,2025Q3 25 Earnings Call2Provided November 4,2025,as part of an oral presentation and is qualified by such,contains forward-looking statements,actual results may vary materially;Amgen discl。

5、UNITED STATESSECURITIES AND EXCHANGE COMMISSIONWashington,D.C.20549FORM 10-Q(Mark One)QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d)OF THE SECURITIES EXCHANGE ACTOF 1934For the quarterly period end。

6、Letter toSHAREHOLDERS20242To My FellowSHAREHOLDERS,ON THE COVER:Jrgen(top left),living with myelomaGina(top right),living with colorectal cancerMJ(bottom left),living with pediatric B-cell acute lymp。

7、UNITED STATESSECURITIES AND EXCHANGE COMMISSIONWashington,D.C.20549Form 10-K(Mark One)ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d)OF THE SECURITIES EXCHANGEACT OF 1934For the fiscal year ended Decem。

8、News ReleaseOne Amgen Center DriveThousand Oaks,CA 91320-1799Telephone 805-447-AMGEN REPORTS FIRST QUARTER 2025 FINANCIAL RESULTSTHOUSAND OAKS,Calif.(May1,2025)-Amgen(NASDAQ:AMGN)today announced fina。

9、UNITED STATESSECURITIES AND EXCHANGE COMMISSIONWashington,D.C.20549FORM 10-Q(Mark One)QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d)OF THE SECURITIES EXCHANGE ACTOF 1934For the quarterly period end。

10、May 1,2025Q1 25 Earnings Call2Provided May 1,2025,as part of an oral presentation and is qualified by such,contains forward-looking statements,actual results may vary materially;Amgen disclaims any d。

11、LETTER TOSHAREHOLDERS20232Amgen performed well in 2023,serving millions of patients around the world with our innovative,life-changing medicines;advancing many promising new first-in-class molecules 。

12、UNITED STATESSECURITIES AND EXCHANGE COMMISSIONWashington,D.C.20549Form 10-K(Mark One)ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d)OF THE SECURITIESEXCHANGE ACT OF 1934For the fiscal year ended Decem。

13、2023 Amgen Inc.All Rights Reserved.2022 Letter to Shareholders|Amgen2TO MY FELLOW SHAREHOLDERS:Amgen performed very effectively in 2022,reaching roughly 10 million patients around the world with our 。

14、2 0 2 0 2020 Letter to Shareholders|AmgenLETTER TO SHAREHOLDERS Robert A.Bradway,Chairman and Chief Executive Officer,Amgen Inc.To My Fellow Shareholders:When I wrote to you one year ago,it was still。

15、2019 Letter to Shareholders|AmgenLETTER TO SHAREHOLDERSRobert A.Bradway,Chairman and Chief Executive Officer,Amgen Inc.To My Fellow Shareholders:As I write this letter,Amgen is approaching a signific。

16、2 0 1 8 L E T T E R TO S H A R E H O L D E R S 2LETTER TO SHAREHOLDERSRobert A.Bradway,Chairman and Chief Executive Officer,Amgen Inc.of 15%and a five-year return of 93%,outperforming our peer group 。

17、LETTER TO SHAREHOLDERS20172To My Fellow Shareholders,Amgen had another successful year in 2017,serving patients around the world with innovative medicines and enabling them to live longer,healthier l。

18、Dear Shareholders,In this letter,I would like to do two things.First,I would like to provide you with an assessment of Amgens performance for 2016.Second,since Amgens business of discovering,developi。

19、Dear Shareholders,2015 was a momentous year for Amgen.It was a year in which we delivered impressive financial results and an unprecedented six innovative new product offerings to the market,each of 。

20、Dear Shareholders,2014 was an extraordinary year for Amgenfinancially,scientifically and organizationally.We moved markedly forward in growing our compelling portfolio of innovative and biosimilar me。

21、Dear Shareholders,2013 was a landmark year for Amgen.We delivered financially for investors as we executed on our core strategies and set the stage for long-term growth.In 2013,revenues increased 8 p。

22、Dear Shareholders,2012 was an exceptional year for Amgen.We delivered for shareholders,positionedthe company for long-term growth,andcontinued to fulfill our mission to servepatients.Revenues rose 11。

23、Amgen 2011 Annual Report and Financial Summary40838_cvr.indd 140838_cvr.indd 13/15/12 9:01 AM3/15/12 9:01 AM*“Adjusted”earnings per share and“adjusted”R&D expenses are non-GAAP fi nancial measure。

24、Amgen 2010 Annual Reportand Financial Summary3/9/11 12:32 PM3/9/11 12:32 PMAbout AmgenAmgen discovers,develops,manufactures,and delivers innovative human therapeutics.A biotechnology pioneer since 19。

25、Amgen 2009 Annual Report and Financial SummaryAmgen Inc.One Amgen Center DriveThousand Oaks,CA 91320-About Amgen2010 Amgen Inc.All rights reserved.MC45347-AAmgen discovers,develops,manufactures,and d。

26、Amgen 2008 Annual Report and Financial SummaryProductsAmgen discovers,develops,manufactures and delivers innovative human therapeutics.A biotechnology pioneer since 1980,Amgen was one of the fi rst c。

27、 2008 Amgen Inc.All rights reserved.MC39651Amgen Inc.One Amgen Center DriveThousand Oaks,CA 91320-Amgen 2007 Annual Report and Financial SummaryAmgen is a biotechnology pioneer with a mission to serv。

28、Amgen 2006 Annual ReportOur Promise 2007 Amgen Inc.All rights reserved.MC36222 660M/3-07“When I make controlling my disease a priority,I can keep my commitments to my family and my business.”*Defined。

29、Amgen Inc.One Amgen Center DriveThousand Oaks,CA91320- 2006 Amgen Inc.All rights reserved.ABOUT AMGENAmgen discovers,develops and delivers innovative human therapeutics.A biotechnology pioneer since 。

30、Amgen Inc.One Amgen Center Drive Thousand Oaks,CA 91320- 2005 Amgen Inc.All rights reserved.MC25288 800M/3-05Inspired science.Defining moments.Amgen 2004 Annual ReportAbout Amgen Amgen is a leading h。

31、What we do It starts with a flash of insight a potentially life-changing discovery.And then the really hard work begins.For more than two decades,Amgen has pursued scientific discovery and technologi。

32、“It meansa world ofAmgen 2002 Annual Reportdifferencefor me.”Weve alwaysbeen clear at Amgenabout our centralaspiration.Were striving to be thebest human therapeutics company.It is a daring,even daunt。

33、2021ENVIRONMENTAL,SOCIAL&GOVERNANCE REPORTIntroductionCOVID-19 Response2|ENVIRONMENTAL,SOCIAL&GOVERNANCE REPORT 2021Healthy PeopleHealthy SocietyHealthy PlanetA Healthy AmgenAppendixCorporate。

34、A LifeWorthLivingA m g e n2001 Annual ReportContents1Letter to Stockholders2Selected Financial Information6Financial Performance9Anemia13Cancer17Inflammation21R&D Targets24Products and Product Ca。

35、Amgen 2015 Environmental Sustainability Report Highlights2Highlighted by our launch of six innovative products,2015 was a year in which Amgen advanced our strategy for long-term growth.We delivered n。

36、Amgen 2000 Annual Reportdramatically improving peoples livesvitality freedomdetermination confidenceindependence agilityContentsSelected Financial InformationLetter to the ShareholdersChronic Kidney 。